Overview

This trial is active, not recruiting.

Condition missing teeth
Treatments autogenous bone graft, inductos, augmentation surgery
Phase phase 3
Sponsor University of Zurich
Start date February 2011
End date December 2017
Trial size 24 participants
Trial identifier NCT01541345, 2012DR2009

Summary

Since there are no clinical studies available comparing the gold standard (autogenous bone graft plus resorbable membrane) to the promising combination of xenogenic bone graft loaded with rhBMP-2 in combination with a collagen membrane for localized ridge augmentation, the present exploratory study has been designed.

The aim of the present study is therefore to test whether or not the application of a xenogenic bone block loaded with rhBMP-2 will results in clinically, radiographically and histologically similar outcomes as the gold standard (autogenous bone block) for the regeneration of chronic ridge defects.

The investigators expect that there is no difference in bone quantity and quality between the two methods and that the use of the test treatment will be more user and patient friendly according to the patient perception/acceptance since no second surgical site will be necessary as well as cause less complications.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking open label
Primary purpose supportive care
Arm
(Active Comparator)
Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland). These course of action is well documented in the literature and standard procedures.
autogenous bone graft
Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland)
(Experimental)
The bone augmentation will be performed using a deproteinized bovine bone mineral (DBBM) block (Bio-Oss Spongiosa Block®, Geistlich Parma AG, Wolhusen, Switzerland) and a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland) similarly to the control group. In addition, DBBM will be loaded with rhBMPH-2 (InductOs®, Pfizer AG, Zurich, Switzerland).
inductos
CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane). One time application at augmentation surgery.
augmentation surgery
CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane)

Primary Outcomes

Measure
Bone quality/quantity
time frame: 4 month after augmentation surgery

Secondary Outcomes

Measure
Complications
time frame: 8 days and 4 month after augmentation surgery
Bone quantity
time frame: at screening, augmentation surgery, suture removal, and during follow-up
Patient's perception/acceptance
time frame: 8 days after augmentation surgery

Eligibility Criteria

Male or female participants from 20 years up to 75 years old.

Inclusion Criteria: - requiring implant therapy for the reconstruction of 1 to 4 missing teeth - revealing insufficient bone volume for implant placement (cases where less than 50% of the implant surface would be surrounded by native bone) requiring bone augmentation procedure Exclusion Criteria: - Medication with a contraindication for implant therapy - Previous administration of InductOs - Skeletal immaturity - Any active malignancy or patient undergoing treatment for a malignancy - An active infection at the operative site - Persistent compartment syndrome or neurovascular residua of compartment syndrome - Pathological fractures such as those observed in (but not limited to) Paget's disease or in metastatic bone - Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product, - Contraindications on ethical grounds, - Pregnancy, - Intention to become pregnant during the course of the study, - Breast feeding, - Treatment with other investigational products, - Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc), - Known or suspected non-compliance, drug or alcohol abuse, - Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia or confusional state of the subject, - Participation in another study with investigational drug within the 30 days preceding and during the present study, - Previous enrolment into the current study, - Enrolment of the investigator, his/her family members, employees and other dependent persons, - Patients where autogenous bone cannot be harvested.

Additional Information

Official title A Phase III, Randomized, Controlled Clinical Trial of Lateral Ridge Augmentation Using Autogenous Bone Blocks or Xenogenic Bone Block Grafts Loaded With Recombinant Human Bone Morphogenic Protein 2
Principal investigator Daniel S Thoma, Dr.
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by University of Zurich.